Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post Depomed Deal Flop, Horizon Buys Crealta For $510m

This article was originally published in Scrip

Executive Summary

Horizon Pharma plc has moved on from its failed $1.7bn attempt to buy Depomed Inc. with the $510m cash purchase of Crealta Holdings LLC, which bought the developer of specialty gout drug Krystexxa (pegloticase) out of bankruptcy two years ago for $120.4m.

You may also be interested in...



Horizon Ramps Teprotumumab Launch Plans Into High Gear

With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).

Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill

Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.

Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease

Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.

Topics

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel